Gilead’s lenacapavir has been on the market since 2022, when it was approved in the U.S. as Sunlenca for twice-yearly ...
The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. marketing ...
Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer (NSCLC) has narrowed.
After dodging a layer of U.S. scrutiny thus far, Chinese CDMO WuXi AppTec is back in the government’s crosshairs. The company is now listed on the U.S. Department of War’s newly updated roster of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results